Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders-Reference-Cited by-同舟云学术

Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders

Published:2017-11-12 Issue:12 Volume:4 Page:877-887
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann Clin Transl Neurol

Author:

Krueger Darcy A.¹^ORCID,Sadhwani Anjali²,Byars Anna W.¹,de Vries Petrus J.³,Franz David N.¹,Whittemore Vicky H.⁴,Filip-Dhima Rajna⁵,Murray Donna⁶⁷,Kapur Kush⁵,Sahin Mustafa⁵^ORCID

Affiliation:

1. Division of Neurology; Department of Pediatrics; Cincinnati Children's Hospital Medical Center; University of Cincinnati; Cincinnati Ohio

2. Department of Psychiatry; Boston Children's Hospital and Harvard Medical School; Boston Massachusetts

3. Division of Child & Adolescent Psychiatry; University of Cape Town; Cape Town South Africa

4. National Institute of Neurological Disorders and Stroke; National Institutes of Health; Bethesda Maryland

5. Department of Neurology; Boston Children's Hospital; Harvard Medical School; Boston Massachusetts

6. Autism Speaks; Boston Massachusetts

7. Division of Developmental & Behavioral Pediatrics; Department of Pediatrics; Cincinnati Children's Hospital Medical Center; University of Cincinnati; Cincinnati Ohio

Funder

Novartis Pharmaceuticals Corporation

Autism Speaks

Tuberous Sclerosis Alliance

Publisher

Wiley

Subject

Clinical Neurology,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/acn3.494/fullpdf

Reference57 articles.

1. mTOR signaling in growth control and disease;Laplante;Cell,2012